347840-95-3

Basic information

• Product Name: 4-(3,4-DIMETHOXY-PHENYL)-5-METHYL-2 H-PYRAZOL-3-YLAMINE
• Synonyms: ASISCHEM D08261;4-(3,4-DIMETHOXY-PHENYL)-5-METHYL-2 H-PYRAZOL-3-YLAMINE;AKOS BBS-00002648;4-(3,4-dimethoxyphenyl)-3-methyl-1H-pyrazol-5-amine;[4-(3,4-dimethoxyphenyl)-5-methyl-1H-pyrazol-3-yl]amine;4-(3,4-dimethoxyphenyl)-5-methyl-1H-pyrazol-3-amine;BAS 06804253;EU-0009687
• CAS NO: 347840-95-3
• Molecular Formula: C₁₂H₁₅N₃O₂
• Molecular Weight: 233.27
• Mol File: 347840-95-3.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(3,4-DIMETHOXY-PHENYL)-5-METHYL-2 H-PYRAZOL-3-YLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-DIMETHOXY-PHENYL)-5-METHYL-2 H-PYRAZOL-3-YLAMINE(347840-95-3)
• EPA Substance Registry System: 4-(3,4-DIMETHOXY-PHENYL)-5-METHYL-2 H-PYRAZOL-3-YLAMINE(347840-95-3)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 347840-95-3(Hazardous Substances Data)

Upstream product

• 93-17-4 3,4-dimethoxyphenylacetonitrile 
• 18133-46-5 α-(3,4-dimethoxyphenyl)acetoacetonitrile 

Downstream Products

• 900297-43-0 3-(3,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-ol 
• 906217-65-0 C₁₈H₁₉N₃O₃ 
• 838854-60-7 4-[1-methyl-7,8-bis(methyloxy)-3H-pyrazolo[3,4-c]isoquinolin-5-yl]phenol trifluoroacetate 
• 900295-57-0 7-chloro-3-(3,4-dimethoxyphenyl)-2,5-dimethylpyrazolo[1,5-a]pyrimidine 

Relevant articles and documents

PYRAZOLO[1,5-A]TRIAZIN-4-AMINE DERIVATIVES USEFUL IN THERAPY

A compound of formula (I), or a pharmaceutically acceptable salt thereof, useful in therapy, in particular in the treatment of a viral infection.

Phenoxide leaving group SNAr strategy for the facile preparation of 7-amino-3-aryl pyrazolo[1,5-a]pyrimidines from a 3-bromo-7-phenoxypyrazolo[1,5-a]pyrimidine intermediate

We have discovered a 3-bromo-7-phenoxypyrazolo[1,5-a]pyrimidine intermediate that allows for the direct sequential funtionalization of the 3-position and 7-position of a pyrazolo[1,5-a]pyrimidine scaffold. The intermediate and general method described herein offer an improvement over prior methods, particularly in cases where multiple unique 3-aryl substituents are to be incorporated in conjunction with multiple unique 7-amino substituents.

Optimization of 3-phenylpyrazolo[1,5-a]pyrimidines as potent corticotropin-releasing factor-1 antagonists with adequate lipophilicity and water solubility

In our efforts to identify potent CRF1 antagonists with proper physicochemical properties, a series of 3-phenylpyrazolo[1,5-a]pyrimidines bearing polar groups, such as amino, hydroxyl, methoxy, sulfoxide, were designed and synthesized. Several positions of the core structure were identified, where a polar group was tolerated with slight reduction in receptor binding. NBI 30545 (18n) was found to have good binding affinity and potent antagonistic activity at the human CRF1 receptor. Moreover, this compound had proper lipophilicity (logD=2.78) and good solubility in water (>10mg/mL), and exhibited good plasma and brain exposure when given orally.